{"title":"肺动脉高压的证据和悬而未决的问题:第五届法国肺动脉高压网络会议的启示。","authors":"Athénaïs Boucly , Laurent Bertoletti , Charles Fauvel , Mélanie Gallant Dewavrin , Christian Gerges , Julien Grynblat , Christophe Guignabert , Sébastien Hascoet , Xavier Jaïs , Etienne-Marie Jutant , Nicolas Lamblin , Olivier Meyrignac , Marianne Riou , Laurent Savale , Cécile Tromeur , Ségolène Turquier , Simon Valentin , Gérald Simonneau , Marc Humbert , Olivier Sitbon , David Montani","doi":"10.1016/j.resmer.2024.101123","DOIUrl":null,"url":null,"abstract":"<div><p>Pulmonary hypertension (PH) continues to present significant challenges to the medical community, both in terms of diagnosis and treatment. The advent of the updated 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines has introduced pivotal changes that reflect the rapidly advancing understanding of this complex disease. These changes include a revised definition of PH, updates to the classification system, and treatment algorithm. While these guidelines offer a critical framework for the management of PH, they have also sparked new discussions and questions. The 5th French Pulmonary Hypertension Network Meeting (Le Kremlin-Bicêtre, France, 2023), addressed these emergent questions and fostering a deeper understanding of the disease's multifaceted nature. These discussions were not limited to theoretical advancements but extended into the practical realms of patient management, highlighting the challenges and opportunities in applying the latest guidelines to clinical practice.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101123"},"PeriodicalIF":2.2000,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evidence and unresolved questions in pulmonary hypertension: Insights from the 5th French Pulmonary Hypertension Network Meeting\",\"authors\":\"Athénaïs Boucly , Laurent Bertoletti , Charles Fauvel , Mélanie Gallant Dewavrin , Christian Gerges , Julien Grynblat , Christophe Guignabert , Sébastien Hascoet , Xavier Jaïs , Etienne-Marie Jutant , Nicolas Lamblin , Olivier Meyrignac , Marianne Riou , Laurent Savale , Cécile Tromeur , Ségolène Turquier , Simon Valentin , Gérald Simonneau , Marc Humbert , Olivier Sitbon , David Montani\",\"doi\":\"10.1016/j.resmer.2024.101123\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Pulmonary hypertension (PH) continues to present significant challenges to the medical community, both in terms of diagnosis and treatment. The advent of the updated 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines has introduced pivotal changes that reflect the rapidly advancing understanding of this complex disease. These changes include a revised definition of PH, updates to the classification system, and treatment algorithm. While these guidelines offer a critical framework for the management of PH, they have also sparked new discussions and questions. The 5th French Pulmonary Hypertension Network Meeting (Le Kremlin-Bicêtre, France, 2023), addressed these emergent questions and fostering a deeper understanding of the disease's multifaceted nature. These discussions were not limited to theoretical advancements but extended into the practical realms of patient management, highlighting the challenges and opportunities in applying the latest guidelines to clinical practice.</p></div>\",\"PeriodicalId\":48479,\"journal\":{\"name\":\"Respiratory Medicine and Research\",\"volume\":\"86 \",\"pages\":\"Article 101123\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-06-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory Medicine and Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590041224000394\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Medicine and Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590041224000394","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
摘要
肺动脉高压(PH)在诊断和治疗两方面都给医学界带来了巨大挑战。2022 年更新的欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)指南的问世带来了关键性的变化,反映出人们对这种复杂疾病的认识正在迅速发展。这些变化包括修订 PH 的定义、更新分类系统和治疗算法。这些指南为 PH 的治疗提供了重要框架,同时也引发了新的讨论和问题。第五届法国肺动脉高压网络会议(2023 年,法国 Le Kremlin-Bicêtre)讨论了这些新出现的问题,并促进了对该疾病多面性的深入了解。这些讨论并不局限于理论上的进步,而是延伸到患者管理的实际领域,强调了将最新指南应用于临床实践的挑战和机遇。
Evidence and unresolved questions in pulmonary hypertension: Insights from the 5th French Pulmonary Hypertension Network Meeting
Pulmonary hypertension (PH) continues to present significant challenges to the medical community, both in terms of diagnosis and treatment. The advent of the updated 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines has introduced pivotal changes that reflect the rapidly advancing understanding of this complex disease. These changes include a revised definition of PH, updates to the classification system, and treatment algorithm. While these guidelines offer a critical framework for the management of PH, they have also sparked new discussions and questions. The 5th French Pulmonary Hypertension Network Meeting (Le Kremlin-Bicêtre, France, 2023), addressed these emergent questions and fostering a deeper understanding of the disease's multifaceted nature. These discussions were not limited to theoretical advancements but extended into the practical realms of patient management, highlighting the challenges and opportunities in applying the latest guidelines to clinical practice.